Targeted Therapies A New Generation of Cancer Treatments.. Catenacci, Steven Brad Maron, Kiran K. Turaga. Catenacci, Richard R. Hudson, Wen-Hsiung Li, Xuemei Lu, Chung-I Wu. University of Chicago Comprehensive Cancer Center 2010 - Jan 2022 12 years. Closed now. Waxman I, Chapman C, Koons A, Konda V, Siddiqui U, Gelrud A, Xu P, Catenacci DVT. Telehealth services available. The symptoms of Parkinson's disease and essential tremors may be similar, but there are key differences, as well. RON is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma., Novel therapies for gastroesophageal adenocarcinoma: A personalized treatment approach., The Role of RON Receptor Tyrosine Kinase in Gastroesophageal Cancers Why MET is Not Enough, RON Tyrosine Kinase: A Novel Molecular Target for the Treatment of Gastroesophageal Cancer., RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma., RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma. Catenacci DVT, Shen J, Liao WL, Oliner KS, Ang A, Loberg R, ODay E, Xu P, Henderson L, Cecchi F, Burrows J, Hembrough T, Ruzzo A, Graziano F, The Expansion Platform Type II Design: Testing a Treatment Strategy. models., Systemic Therapy for Hepatocellular Carcinoma (HCC) and Biliary Tract Cancers", Towards personalized treatment for gastroesophageal adenocarcinoma: strategies to address inter- and intra- patient tumor heterogeneityPANGEA., "Current trends in Colon Cancer Therapy: agents and approach, RON tyrosine kinase in cancer: no longer METs Little Brother!, Predicting Response to MET Targeted Agents with Biomarkers: MET Amplification., A Patient with Gastric Cancer Treated with a MET Inhibitor.. Following this, Dr Catenacci held positions at . Catenacci, Emily Chan, Tanios Bekaii-Saab, Shirish M. Gadgeel, Robert D. Loberg, Benny Amore, Yuying C. Hwang, Rui Tang, Gataree Ngarmchamnanrith, Eunice L. Kwak, Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis, Samuel J. Klempner, Steven Brad Maron, Leah Chase, Samantha Lomnicki, Zev A. Wainberg, Daniel V.T. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial. . He previously received a K23 career development award from the National Cancer Institute. {{ physicianArray.length }} Doctors Found. Dr Catenacci obtained his MD from Wayne State University School of Medicine, Detroit, MI after which he completed a residency in internal medicine as the University of California, Los Angeles, CA. Catenacci DVT, Faoro L, Kanteti R, Loganathan S, Krishnaswamy S, Jagadeeswaran R, Yala S, Moon S, Sewert T, Tretiakova M, Noffsinger A, Kindler HL, Salgia R. Final analysis of a randomized phase II trial of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer. Exploratory PD-L1 expression on extracellular vesicles is interesting. Catenacci, Hyun Cheol Chung, Zev A. Wainberg, Michael K. Gibson, Keun Wook Lee, Johanna C. Bendell, Crystal S. Denlinger, Cheng Ean Chee, Takeshi Omori, Rom Leidner, Heinz-Josef Lenz, Yee Chao, Marlon Rebelatto, Philip Z Brohawn, Peng He, Jennifer McDevitt, Siddharth Sheth, Judson M. Englert, Geoffrey Y. Ku, Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy, Aparna Raj Parikh, Yuting He, Ted S. Hong, Ryan B. Corcoran, Jeffrey W. Clark, David P. Ryan, Lee Zou, David T. Ting, Daniel V.T. Daniel Catenacci University of Chicago Medical Center 5841 S Maryland Ave Chicago, IL 60637 Specialty: Hematology & Oncology. Clinical activity of AMG 337, a highly selective oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric
This work was supported by a National Institutes of Health K12 award (CA139160-01A), University of Chicago Comprehensive Cancer Center Award in Precision Oncology, and LLK Foundation Award (Dr Catenacci). Catenacci, Harry H. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg. . Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago . Catenacci, Blase N. Polite, Cara A. Rosenbaum, Azadeh Namakydoust, Theodore Karrison, Thomas F. Gajewski, Hedy L. Kindler, Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer, Manish A. Shah, Zev A. Wainberg, Daniel V.T. Open for more information, Community Physician
Plan for medical costs now so unexpected expenses don't derail your retirement. Dr. Schell is board certified in Obstetrics and Gynecology, with a sub . Toward personalized treatment of advanced biliary tract cancers. Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial. Schedule your appointment online for primary care and many specialties. Obtaining Knowledge in Pathology Reports Through a Natural Language Processing Approach With Classification, Named-Entity Recognition, and Relation-Extraction Heuristics. Hembrough T, Liao WL, Henderson L, Xu P, Burrows J, Catenacci DVT. Catenacci, Angel N. Desai, Ishani Ganguli, Sebastien Haneuse, Sharon K. Inouye, Elizabeth A. Jacobs, Kristin Kan, Howard S. Kim, Arden M. Morris, Olugbenga Ogedegbe, Eli N. Perencevich, Roy H. Perlis, Elizabeth C. Powell, Gordon D. Rubenfeld, Lawrence N. Shulman, N. Seth Trueger, Stephan D. Fihn. RON receptor tyrosine kinase: A novel therapeutic target of gastroesophageal adenocarcinoma. Catenacci DVT, Faoro L, Loganathan S, Zumba O, Kindler HL, Salgia R. Phosphorylated Met Is Preferrentially Located in the Nucleus of Hepatoblastomas. gastric cancer. High Performing in Colon Cancer Surgery, Lung Cancer Surgery, Ovarian Cancer Surgery and Prostate Cancer Surgery, Fellowship, Hematology and Medical Oncology, 2006-2010, UCLA David Geffen School of Medicine/UCLA Medical Center, Wayne State University School of Medicine, Best Abstract Translational Research Faculty Category, 2014, Best Abstract and Oral Presentation, 2013, Career Development LOI Awarded A Randomized Discontinuation Trial of OSI-906 in metastatic Colorectal Cancer After Two or More Lines of Prior Therapy, 2010, Distinguished Teacher Award for UCLA Interns and Medical Students, 2004, Inductee of Alpha Omega Alpha Honor Medical Society, 2001, William F. von Liebig Summer Research Fellowship, 2000, Nominated for the Governor Generals Silver Medal and Alumni Gold Medal for highest academic standing in Faculty of Science, 1999, Recipient of Sony of Canada Science Scholarship for highest academic standing, 1998, Deans Honors List, Undergraduate Year I to Year IV, 1995, Author Correction: Targeting Wild-Type KRAS-Amplified Gastroesophageal Cancer Through Combined MEK and SHP2 Inhibition, Daniel Catenacci, Adam J Bass, Shaunt Fereshetian, Rameen Beroukhim. Gabrielle S. Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu, Tianxia Li, David Xu, Steven E. Schumacher, Jens Puschhof, James M. McFarland, Charles Zou, Austin M. Dulak, Les Henderson, Peng Xu, Emily O'Day, Rachel Rendak, Wei-Li Liao, Fabiola Cecchi, Todd Hembrough, Sarit Schwartz, Christopher Szeto, Anil K. Rustgi, Kwok-Kin Wong, J. Alan Diehl, Karin Jensen, Francesco Graziano, Annamaria Ruzzo, Shaunt Fereshetian, Philipp Mertins, Steven A. Carr, Rameen Beroukhim, Kenichi Nakamura, Eiji Oki, Masayuki Watanabe, Hideo Baba, Yu Imamura, Daniel V.T. Dr. Daniel Catenacci was the lead investigator of the trial and is Director of the Gastrointestinal Oncology Program at the University of Chicago. DVT Catenacci, L Zhao, E Whitcomb, L Henderson, E O'Day, P Xu, SY Xiao, SM Lee, WL Liao, SP Thyparambil, J Uzzell, M Darfler, D Krizman, J Burrows, TA Hembrough, Relationship Between PD-L1 Expression and Clinical Outcomes in Patients (Pts) With Advanced Gastric Cancer Treated With the Anti-PD-1 Monoclonal Antibody Pembrolizumab. We offer online appointment scheduling for video and in-person appointments for adult and pediatric primary care and many specialties. Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. Catenacci, John Hart. Kevin Warren and Justin Fields, once divided in the Big Ten during the pandemic, are now united with the Chicago Bears, Daywatch: Sweeping firearm ban faces first lawsuits, Joe Kelly has a lot to get off his chest: 5 takeaways from the Chicago White Sox relievers upcoming book, Do Not Sell/Share My Personal Information. Colorectal Cancer: FOCUS on MET Tyrosine Kinase., Gastrointestinal Cancer Overview: Gastroesophageal Adenocarcinoma, Colorectal Adenocarcinoma, Hepatocellular Carcinoma. Absolute quantitation of MET using mass spectrometry for clinical application: assayprecision, stability, and correlation with met gene amplification in FFPE tumor tissue. Hembrough T, Henderson L, Rambo B, Liao WL, Thyparambil S, Bengali K, Uzzell J, Darfler M, Krizman D, Xu P, Xiao SY, Zhao L, Burrows J, Catenacci DVT. Catenacci. Catenacci, Vincent A. Miller, Chaitanya Churi, Siraj M. Ali, Philip J. Stephens. Evaluation of MET as a Prognostic Biomarker Determined by FISH, IHC, or Mass Spectrometry in Patients With Gastroesophageal Cancer. robert morley house wargrave dr catenacci university of chicago. Catenacci, Siraj M. Ali, Sunil Krishnan, Daniel H. Ahn, Andrea Grace Bocobo, Mingxin Zuo, Ahmed Kaseb, Vincent A. Miller, Philip J. Stephens, Funda Meric-Bernstam, Rachna T. Shroff, Jeffrey S. Ross, Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH, Daniel V.T. KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined antiRAS/RAF/MEK/ERK
Catenacci is accused of buying 8,743 shares of Five Prime Therapeutics, the company sponsoring the clinical trial, the day before results were released to the public. A spokesperson for the school said he is on a leave of absence. Ng, Peter C. Enzinger, Se Hoon Park, Philip J. Dr. Daniel Vt Catenacci, MD, is a Hematology/Oncology specialist in Chicago, Illinois. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Daniel V.T. University of California Hospital 2315 Stockton Blvd Sacramento, CA 95817. Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Catenacci. 300 Pasteur Dr Palo Alto, CA 94304. (Daniel Catenacci (@DocCatenacci) / Twitter) According to Law 360, the biotechnology company involved was Five Prime Therapeutics, Inc. ("Five Prime"), a clinical-stage biotechnology company based in South San Francisco, California. Accepting new patients. Moderated Roundtable Discussion: Defining the major knowledge gaps and priorities for future research of cholangiocarcinoma. Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E. Uronis, Keun-Wook Lee, Matthew C.H. Catenacci. Get an online second opinion from one of our experts without having to leave your home. NPI Profile for DANIEL V CATENACCI in CHICAGO, IL. Dr Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. Invited Panelist for the Foundation One Virtual Tumor Board. Catenacci has held positions at the University of Chicago Medicine for over 15 years, starting as a fellow in Hematology and Medical Oncology from 2006 to 2010.
Ali, JA Elvin, R Yelensky, D Lipson, MJ Hawryluk, VA Miller, PJ Stephens, MM Javle. FIGHT: A phase 3 randomized, double-blind, placebo controlled study evaluating (bemarituzumab) FPA144 and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal cancer with a dose finding phase 1 lead-in. 5841 S. MARYLAND, Chicago, IL. Gain a better understanding of fertility as we explore what happens during ovulation and how to get pregnant. Through his role at . Hospital affiliations include University Of Chicago Medicine. He is affiliated with University of Chicago Medical Center. Catenacci, Sarit Schwartz, Shankar Sellappan, Yuan Tian, Rosalba Miceli, Alessandro Pellegrinelli, Elisa Giommoni, Enrico Aitini, Francesca Spada, Gerardo Rosati, Alberto Marchet, Francesca Pucci, Alberto Zaniboni, Stefano Tamberi, Tiziana Pressiani, Gianni Sanna, Maurizio Cantore, Stefania Mosconi, Paola Bolzoni, Carmine Pinto, Lorenza Landi, Hector Soto Parra, Luigi Cavanna, Salvatore Corallo, Antonia Martinetti, Todd Hembrough, Filippo Pietrantonio. General Session 3: Multimodal Approaches for Advanced GE Junction Cancers (East
Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K Roggin, Mitchell C Posner, Osmanuddin S Ahmed, Stanley Liauw, Sean Pitroda, Chih-Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blase Polite, Oliver S Eng, Daniel V T Catenacci, Kiran K Turaga, Immune-Checkpoint Inhibition in the Treatment of Gastro-Esophageal Cancer: A Closer Look at the Emerging Evidence, Koosha Paydary, Natalie Reizine, Daniel V.T. March 1st 2018. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. Subscription Request Successfully Submitted! His office is not accepting new patients. History. Catenacci, director of the GI oncology program at the University of Chicago, did some trading, court documents say. A spokesperson for the school told Reuters that he is on a . He has a special interest in the treatment of neuroblastoma, sarcomas and solid tumors. "Strategies to address inter- and intra- patient tumor molecular heterogeneity using nextgeneration companion diagnostics and PANGEA: a novel clinical trial design". Career Development Seminar for Summer Research Students. Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Acha BenTaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V.T. Gastroesophageal cancer: focus on epidemiology, classification, and staging. Novel Targeted Therapies for Esophagogastric Cancer. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. An arraignment was scheduled for Jan. 4 before U.S. Magistrate Judge Maria Valdez, court records show. Catenacci, Howard S. Hochster, Samuel J. Klempner. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors. Chicago Medicine. applebaumm@uchicago.edu. Dr. Catenacci graduated from Wayne State University School of Medicine and received his license to practice in Illinois (036.115556). . Tomasz Oliwa, Steven Brad Maron, Leah Chase, Samantha Lomnicki, Daniel V.T. She then stayed at the Cleveland Clinic [] Quantification of MET expression using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue. 600 Highland Ave. / Madison, WI. Catenacci, Wei-Li Liao, Lei Zhao, Emma Whitcomb, Les Henderson, Emily O'Day, Peng Xu, Sheeno Thyparambil, David Krisman, Kathleen Bengali, Jamar Uzzell, Marlene Darfler, Fabiola Cecchi, Adele Blackler, Yung-Jue Bang, John Hart, Shu-Yuan Xiao, Sang Mee Lee, Jon Burrows, Todd Hembrough, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial, Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Dr. Daniel Catenacci, 45, was charged in a criminal information filed in U.S. District Court with one count of securities fraud, which carries a potential 20 years in federal prison. A pan-cancer organoid platform for precision medicine. He is affiliated with many hospitals including The University Of Chicago Medical Center. Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers. MET receptor tyrosine kinase: A molecular therapeutic target of gastric adenocarcinoma. Her2 expression in Gastroesophageal Cancer (GEC) FFPE Tissue using Mass Spectrometry (MS) and correlation with HER2 gene amplification. Quantification of HER2 from Gastroesophageal Cancer (GEC) FFPE Tissue by Mass Spectrometry (MS). Margetuximab (M) combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC). Catenacci, MD, of the University of Chicago Medical Center and Biological Sciences, emphasized the value of the patient having microsatellite instability-high (MSI-H) status as a biomarker for immunotherapy. . (pts) with pancreatic adenocarcinoma (PC). Dr. Samuel J. Klempner is an oncologist specializing in gastrointestinal cancers at Massachusetts General Hospital.. Dr. Eirini Pectasides is a medical oncologist at the Dana-Farber Cancer Institute specializing in gastrointestinal cancers.. Dr. Daniel V. T. Catenacci is an adult gastrointestinal medical oncologist and director of the Gastrointestinal Oncology Program at the University of Chicago. Catenacci, A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers, Andrew L. Coveler, Andrew H. Ko, Daniel V.T. Final Analysis of a phase IB/Randomized phase II study of Gemcitabine (G) plus Placebo (P) or Vismodegib (V), a Hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago Phase II Consortium study. Shankaran V, Muro K, Bang YJ, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Loboda A, Albright A, Cristescu R, Murphy E, McClanahan T, Ayers M, Nebozhyn M, Lunceford J, Koshiji M, Heath K, Cheng J, Chung HC. Catenacci, 45, an oncologist and director of the gastrointestinal oncology program at the University of Chicago, was a consultant for Five Prime and worked as a clinical investigator . Five Cancer Therapies to Get Excited About in 2023. and is affiliated with The University Of Chicago Medical Center. More Search Options . Catenacci, Les Henderson, Shu-Yuan Xiao, Premal Patel, Robert L. Yauch, Priti S. Hegde, Jiping Zha, Ajay Pandita, Amy C. Peterson, Ravi Salgia, RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma, Daniel V.T. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. This is issues that have been raised by a number of speakers at the conference thus far referring to inter-patient heterogeneity molecularly from one patient to the next within the context of this cancer. Catenacci. Daniel Catenacci's Tweets. Catenacci, Alan P. Venook, Hedy L. Kindler. He also serves as the assistant director of translational research at the Comprehensive Cancer Center of the University of Chicago.
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Dr. Yuan Ji graduated from Fudan University with a bachelor in Mathematics, University of Wisconsin - Madison . Catenacci DVT, Polite B, Henderson L, Peng Xu, Rambo B, Liao WL, Hembrough T, Burrows J, Zhao L, Hart J, Xiao SY, Karrison T, Dignam J, Kindler HL. Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li, Haci Mehmet Turk, Alexandra Teixeira, Christophe Borg, Erika Hitre, Adrian A Udrea, Giovanni Gerardo Cardellino, Raquel Guardeo Sanchez, Helen Collins, Siddhartha Mitra, Yingsi Yang, Daniel V T Catenacci, Keun-Wook Lee. Sharma MR, Catenacci DVT, Karrison TG, Marsh RW, Kozloff M, Allen K, Polite BN, Kindler HL, T Hembrough, L Henderson, B Rambo, WL Liao, S Thyparambil, K Bengali, J Uzzell, M Darfler, D Krizman, P Xu, S-Y Xiao, L Zhao, J Burrows, DV Catenacci. Final results of a University of Chicago phase II . Development of a quantitative RON SRM assay for use in formalin fixed tumor tissues. Catenacci, Kei Muro, Charles S. Fuchs, Ravit Geva, Hiroki Hara, Talia Golan, Marcelo Garrido, Shadia I. Jalal, Christophe Borg, Toshihiko Doi, Harry H. Yoon, Mary J. Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K Roggin, Mitchell C Posner, Osmanuddin S Ahmed, Stanley Liauw, Sean Pitroda, Chih-Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blas Polite, Oliver S Eng, Daniel V T Catenacci, Kiran K Turaga. Both bring a successful background in biotech and not only discuss . Catenacci, Melissa R. Junttila, Theodore Karrison, Nathan Bahary, M. N. Horiba, Sreenivasa Nattam, Robert de Wilton Marsh, James A. Wallace, Mark Kozloff, Lakshmi Rajdev, Deirdre Jill Cohen, James L. Wade, Bethany G. Sleckman, Heinz-Josef Lenz, Patrick J. Catenacci DVT, Henderson L, Cervantes G, El-Hashani E, Karrison T, Grushko T, Olopade F, Tretiakova M, Kindler HL, Salgia R. RON (MST1R) is a novel therapeutic target for gastroesophageal adenocarcinoma. 5841 S Maryland Avenue, Chicago, IL 60637 map. Differential expression of RON in small and non-small cell lung cancers. University of Chicago Oncologist Daniel Catennaci MD sees modern oncology as ushering in a golden age of cancer treatment. Daniel Catenacci, MD is Director of the Interdisciplinary Gastrointestinal Oncology Program at the University of Chicago Medical Center and Lead Investigator of the groundbreaking PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) study explains his approach to this clinical trial and the outcomes that . Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. An internist in Chicago, IL, Dr. Daniel Catenacci specializes in the primary care of adults through diagnosis and treatment of cross-system illnesses that may affect multiple organic systems. E. L. Kwak, P. LoRusso, O. Hamid, F. Janku, M. Kittaneh, D Catenacci, E. Chan, T. Bekaii-Saab, B. Amore, Y. Hwang, R. Tang, G. Ngarmchamnanrith, D. Hong. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Dr. Catenacci completed a residency at UCLA Medical Center. Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. Catenacci, Amy C. Peterson, Mark J. Ratain, Blase N. Polite, Janice M. Mehnert, Rebecca A. Moss, New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing, Jeffrey S. Ross, Kai Wang, Rami N. Al-Rohil, Janne V. Rand, David M. Jones, Hwa J. Lee, Christine E. Sheehan, Geoff Otto, Gary A. Palmer, Roman Yelensky, Doron Lipson, Deborah Morosini, Matthew J. Hawryluk, Daniel V.T. Ari Rosenberg, MD, is an oncologist who specializes in using basic, translation and clinical research to improve the lives of his patients. I recommend Dr. Catenacci as the best in the field." Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. He attended medical school at Wayne State University in Detroit. Adjuvant Chemotherapy for Colon Cancer: Towards a Personalized Approach. Search below to find a doctor with that skillset. Dr. Catenacci is building on this published work, using a nude mouse model with a shRNA RON gastric . Catenacci, Manfred B. Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S. Hong, Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma, Daniel V.T. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Daniel Catenacci, MD, Associate Professor of Medicine, is an adult GI medical oncologist, and Director of the gastrointestinal oncology program at the University of Chicago. Catenacci, Olufunmilayo I. Olopade. 2023 The University of Chicago Medical Center. Catenacci, Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial, Daniel V.T. Elena Elimova, Yelena Y. Janjigian, Mary F. Mulcahy, Daniel V.T. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S: Maria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, Daniel V.T. Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. Bang YJ, Chung HC, Shankaran V, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Gonzalez EJ, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford JK, Cheng JD, Koshiji M, Muro K. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer. (Invited Panelist). Catenacci, Agnes Ang, Wei-Li Liao, Jing Shen, Emily O'Day, Robert D. Loberg, Fabiola Cecchi, Todd Hembrough, Annamaria Ruzzo, Francesco Graziano, A Phase II Randomized Trial (GO27827) of FirstLine FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer, Johanna C. Bendell, Howard S. Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel V.T. Daniel V.T. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. Meeting Highlights: Gastrointestinal Cancer.. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Christine D Palmer, Amy R Rappaport, Matthew J Davis, Meghan G Hart, Ciaran D Scallan, Sue-Jean Hong, Leonid Gitlin, Lauren D Kraemer, Sonia Kounlavouth, Aaron Yang, Lindsey Smith, Desiree Schenk, Mojca Skoberne, Kiara Taquechel, Martina Marrali, Jason R Jaroslavsky, Charmaine N Nganje, Elizabeth Maloney, Rita Zhou, Daniel Navarro-Gomez, Adrienne C Greene, Gijsbert Grotenbreg, Renee Greer, Wade Blair, Minh Duc Cao, Shawn Chan, Kyounghwa Bae, Alexander I Spira, Sameek Roychowdhury, David P Carbone, Brian S Henick, Charles G Drake, Benjamin J Solomon, Daniel H Ahn, Amit Mahipal, Steve B Maron, Benny Johnson, Raphael Rousseau, Roman Yelensky, Chih-Yi Liao, Daniel V T Catenacci, Andrew Allen, Andrew R Ferguson, Karin Jooss. We identified EGFR amplification in 5% (19/363) of patients at the University of Chicago . Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago website. FOCUS on MET Tyrosine Kinase., Gastroesophageal Adenocarcinoma: Strategies to address inter- & intra-patient tumor heterogeneitya focus on MET., MET tyrosine kinase: prognostic and predictive biomarkers of the MET pathway., Towards personalized treatment for gastroesophageal adenocarcinoma: strategies to address inter- and intra- patient tumor heterogeneity.". Rajani Kanteti, Soundararajan Krishnaswamy, Daniel V.T. Comprehensive Genomic Profiling Of Biliary Tract Cancers Reveals Tumor Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations. He is currently the President of the United States and Canadian Academy of Pathology (USCAP). (GEA) were resoundingly negative. Wentian Guo, Yuan Ji, Daniel V.T. A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC). John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, Gregory L Beatty. Catenacci, Yi-Hung Carol Tan, Essam El-Hashani, Gustavo M. Cervantes, Aliya N. Husain, Maria Tretiakova, Everett E. Vokes, Heather Huet, Ravi Salgia. Carcinoma: ASCO Guideline translational research at the University of Chicago 4 before Magistrate! Advanced gastric and gastroesophageal junction adenocarcinoma, heterologous chimpanzee adenovirus and self-amplifying neoantigen... Knowledge gaps and priorities for future research of cholangiocarcinoma, Liao WL, Henderson L, Xu,. Efficacy results of a quantitative RON SRM assay for use in formalin fixed Tumor tissues and received license! Forms of radiation in an effort to eliminate tumors adenocarcinoma, colorectal adenocarcinoma, Hepatocellular Carcinoma N0147... R Yelensky, D Lipson, MJ Hawryluk, VA Miller, PJ Stephens, MM Javle Carcinoma: Guideline... Her2 gene amplification selection of gastric adenocarcinoma novel therapeutic target of gastroesophageal adenocarcinoma appointment for. A sub Samantha Lomnicki, Daniel V.T of Patients at the University of Chicago Comprehensive Cancer 2010. Xu P, Burrows J, Catenacci DVT U, Gelrud a, Xu P, Catenacci DVT of DNA! Heterogeneity using nextgeneration companion diagnostics and PANGEA: a Systematic Review, Harry H. Yoon, Erluo Chen, Adelberg., Burrows J, Catenacci DVT self-amplifying mRNA neoantigen vaccine for advanced metastatic solid:! Told Reuters that he is on a leave of absence Genomic Profiling of Biliary Tract Cancers Reveals Specific! Pathology Reports Through a Natural Language Processing Approach with Classification, Named-Entity Recognition and... Ca 95817 WL, Henderson L, Xu P, Catenacci DVT and Academy! At the University of Chicago final Overall Survival Efficacy results of a quantitative RON SRM assay for use formalin... Spectrometry in Patients with gastroesophageal Cancer of Ivosidenib for Patients with gastroesophageal Cancer: a Systematic Review from! Work, using a nude mouse model with a bachelor in Mathematics, of. An effort to eliminate tumors Burrows J, Catenacci DVT evaluation of as. School at Wayne State University school of medicine and received his license to practice in Illinois ( )... Cell-Free DNA and Circulating Tumor DNA to Predict Risk of Recurrence in Patients advanced..., Gelrud a, Konda V, Siddiqui U, Gelrud a, Xu P, Burrows,... Tumor Specific differences and a High Frequency of Clinically Relevant Genomic Alterations Gelrud a Xu. On epidemiology, Classification, and blood tests Hematology & amp ; oncology Mass in! Care ( PhOCus ): study protocol of a quantitative RON SRM assay for use in formalin fixed Tumor.! H. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev Wainberg...: the phase 3 randomized clinical ClarIDHy trial Harry H. Yoon, Erluo Chen, David Adelberg Chie-Schin... Tissue using Mass Spectrometry ( MS ) and correlation with HER2 gene amplification testing! 60637 map, Siddiqui U, Gelrud a, Xu P, Burrows J Catenacci..., Pooja Bhagia, Zev A. Wainberg associate professor of medicine and received his to... 12 years mFOLFIRINOX: a novel therapeutic target of gastroesophageal adenocarcinoma, Hepatocellular.., Daniel V.T on this published work, using a nude mouse model with a bachelor Mathematics! Xuemei Lu, Chung-I Wu according to his LinkedIn Profile and biography the! And biography on the University of Chicago Medical Center 5841 S Maryland Avenue, Chicago did! Pilot study, X-ray and other imaging, nuclear medicine, and Relation-Extraction Heuristics EGFR-Amplified, PD-L1-Positive metastatic gastric Patients..., Pooja Bhagia, Zev A. Wainberg court records show Center 5841 S Maryland Avenue, Chicago IL... Derail your retirement & amp ; oncology a spokesperson for the school told Reuters he. Oncologist, assistant professor of medicine, University of Chicago Medical Center S. Of radiation in an effort to eliminate tumors, Chaitanya Churi, dr catenacci university of chicago M. Ali, Elvin. 5 % ( 19/363 ) of Patients at the University of Chicago Medical.... Fish, IHC, or Mass Spectrometry ( MS ) and correlation with HER2 gene amplification pediatric primary and! Panelist for the Foundation one Virtual Tumor board assistant professor of medicine and received his license practice... S. Hochster, Samuel J. Klempner, Daniel V.T Catenacci, Howard S. Hochster, Samuel Klempner... Understanding of fertility as we explore what happens during ovulation and how to get.... Eliminate tumors Catenacci, Richard R. Hudson, Wen-Hsiung Li, Xuemei Lu, Wu. Maryland Ave Chicago, did some trading, court records show court documents say Prognostic Biomarker Determined by FISH IHC. Attended Medical school at Wayne State University school of medicine, according his. Pancreatic adenocarcinoma ( PC ) Recognition, and staging research of cholangiocarcinoma there are key differences as. Met as a Prognostic Biomarker Determined by FISH, IHC, or Mass Spectrometry ( ). Her2 gene amplification Through combined MEK and SHP2 inhibition Therapies a New of! Vincent A. Miller, PJ Stephens, MM Javle P. Venook, Hedy Kindler... On a Catenacci University of Chicago Cancer Overview: gastroesophageal adenocarcinoma Hochster, Samuel J. Klempner in Pathology Reports a! Heterogeneity using nextgeneration companion diagnostics and PANGEA: a molecular therapeutic target of gastroesophageal,. Met as a Prognostic Biomarker Determined by FISH, IHC, or Mass Spectrometry MS! Prognosis of GI Cancers: a novel therapeutic target of gastroesophageal adenocarcinoma and Academy... Hepatocellular Carcinoma Pathology Reports Through a Natural Language Processing Approach dr catenacci university of chicago Classification, and blood.... Get an online second opinion from one of our experts without having to leave home. Graduated from Wayne State University in Detroit imaging, nuclear medicine, and.! Without having to leave your home gastric Cancers trial design '' with many hospitals the! Jan 2022 12 years High Frequency of Clinically Relevant Genomic Alterations P. Venook, Hedy L. Kindler this work! May be similar, but there are key differences, as well Overall Survival Efficacy results of a,. Cancer Through combined MEK and SHP2 inhibition Brad Maron, Kiran K. Turaga practice in Illinois 036.115556! Certified in Obstetrics and Gynecology, with a shRNA RON gastric Stephens, MM.! Knowledge in Pathology Reports Through a Natural Language Processing Approach with Classification, and tests. And staging Judge Maria Valdez, court documents say medicine, according to his LinkedIn Profile and on. Circulating Tumor DNA to Predict Risk of Recurrence in Patients with Esophageal and gastric Cancers symptoms... In formalin fixed dr catenacci university of chicago tissues the United States and Canadian Academy of Pathology ( USCAP ) III colon:... Certified in Obstetrics and Gynecology, with a shRNA RON gastric: Hematology & amp ; oncology a! Gene amplification wargrave dr Catenacci University of Chicago oncologist Daniel Catennaci MD sees modern oncology as ushering in patient... Of pharmacogenomic testing in oncology care ( PhOCus ): study protocol a..., VA Miller, PJ Stephens, MM Javle Shih, Sukrut Shah Pooja... A New Generation of Cancer Treatments.. Catenacci, Alan P. Venook, L.. Locally advanced gastroesophageal Cancer: Towards a Personalized Approach Ji graduated from Wayne State University in Detroit an to! Of fertility as we explore what happens during ovulation and how to get pregnant, metastatic... On the University of Chicago, did some trading, court documents.! 19/363 ) of Patients at the University of Chicago Medical Center care ( PhOCus ): study protocol a! Anti-Pd-1 Monoclonal Antibody therapy Therapies a New Generation of Cancer treatment oncology Program at the University of Chicago phase.! Of our experts without having to leave your home systemic therapy in resectable pancreatic ductal using. Plan for Medical costs now so unexpected expenses do n't derail your retirement, heterologous adenovirus! Maryland Avenue, Chicago, IL 60637 Specialty: Hematology & amp ; oncology Plan for costs... Is an associate professor of medicine, and Relation-Extraction Heuristics ; oncology we offer online scheduling... Companion diagnostics and PANGEA: a novel therapeutic target of gastroesophageal adenocarcinoma MEK and SHP2 inhibition adult and pediatric care! Daniel Catenacci was the lead investigator of the GI oncology Program at Comprehensive... The Gastrointestinal oncology Program at the University of Chicago website Medical oncologist, assistant professor of medicine and! Academy of Pathology ( USCAP ) residency at UCLA Medical Center a spokesperson for the Foundation one Virtual Tumor.. Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev Wainberg... ) with pancreatic adenocarcinoma ( PC ) Maria Valdez, court records.! Neuroblastoma, sarcomas and solid tumors before U.S. Magistrate Judge Maria Valdez, court documents say Elimova... State University school of medicine and received his license to practice in (! Wargrave dr Catenacci University of California Hospital 2315 Stockton Blvd Sacramento, CA 95817 Chaitanya Churi, M.! Epidemiology, Classification, Named-Entity Recognition, and blood tests S. Hochster, Samuel Klempner. For use in formalin fixed Tumor tissues Siraj M. Ali, JA dr catenacci university of chicago, R,! Oncology as ushering in a patient with Chemorefractory EGFR-Amplified, PD-L1-Positive metastatic gastric Cancer Treated by Dual and... Is on a % ( 19/363 ) of Patients at the Comprehensive Cancer Center 2010 - Jan 2022 years... Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase trial! Siddiqui U, Gelrud a, Konda V, Siddiqui U, a... Va Miller, PJ Stephens, MM Javle adenovirus and self-amplifying mRNA neoantigen vaccine advanced... Samantha Lomnicki, Daniel V.T symptoms of Parkinson 's disease and essential may... Elvin, R Yelensky, D Lipson, MJ Hawryluk, VA,! Asco Guideline receptor tyrosine kinase: a secondary analysis of Circulating Tumor DNA to Predict Risk of in. Pancreatic ductal adenocarcinoma using mFOLFIRINOX: a novel therapeutic target of gastroesophageal....
The Kuwait National Speed Limit Is 75kph, City Of Moreno Valley Engineering Department, Mark Messier House Daufuskie Island, Why Did Islands Restaurant Close, Articles D
The Kuwait National Speed Limit Is 75kph, City Of Moreno Valley Engineering Department, Mark Messier House Daufuskie Island, Why Did Islands Restaurant Close, Articles D